This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sinensky, M. Articles by Dalton, M. Search for Related Content PubMed PubMed Citation Articles by Sinensky, M. Articles by Dalton, M.

An Antibody Which Specifically Recognizes Prelamin A but not Mature Lamin A: Application to Detection of Blocks in Farnesylation-dependent Protein Processing¹

Eleanor Roosevelt Institute, Denver, Colorado 80206

A polyclonal antibody [anti-prelamin A antibody (-PA)] has been obtained against the peptide LLGNSSPRTQSPQN which is proteolytically removed during the farnesylation-dependent processing of prelamin A to mature lamin A. We tested the ability of this antibody to detect inhibition of farnesylation-dependent protein processing of prelamin A. The -PA antibody was shown to immunoprecipitate prelamin A from lovastatin-treated HeLa cells but not mature lamin A from untreated cells. Further studies were performed after antigen-affinity chromatographic purification of the antibody. Western blotting of lovastatin-treated HeLa cell extract demonstrated that the purified -PA antibody recognizes prelamin A. Furthermore, this signal could be competed away by incubation with the peptide. Indirect immunofluorescence helped detect nuclear accumulation of the antigen in response to treatment of HeLa cells with lovastatin or in Chinese hamster ovary K1 cells transiently transfected with a prelamin A mutant blocked in farnesylation. This antibody should be useful for screening compounds that may block any of the three common steps in the farnesylation-dependent processing of proteins (farnesylation, endoproteolysis, and carboxymethylation) since it appears that prelamin A undergoes all of these reactions prior to removal of the antigenic peptide. Inhibitors of these reactions have been proposed as potential anticancer drugs, since they would be expected to block the biological activity of oncogenic p21^ras proteins. Since such screening would be performed most efficiently by enzyme-linked immunosorbent assays, we can detect the accumulation of prelamin A after treatment with lovastatin by performing this procedure as well. Application of -PA in an enzyme-linked immunosorbent assay, which demonstrates the activity of a peptidomimetic farnesyltransferase inhibitor, supports the use of this antibody in large scale screening for inhibitors of farnesylation-dependent protein processing.

¹ This work was supported by Grant BE-29F (M. S.) from the American Cancer Society.

² To whom requests for reprints should be addressed, at Eleanor Roosevelt Institute, 1899 Gaylord St., Denver, CO 80206.

Received 12/ 6/93. Accepted 4/14/94.

This article has been cited by other articles:

				Y. Liu, Y. Wang, A. E. Rusinol, M. S. Sinensky, J. Liu, S. M. Shell, and Y. Zou Involvement of xeroderma pigmentosum group A (XPA) in progeria arising from defective maturation of prelamin A FASEB J, February 1, 2008; 22(2): 603 - 611. [Abstract] [Full Text] [PDF]

				J. E. Lancet, I. Gojo, J. Gotlib, E. J. Feldman, J. Greer, J. L. Liesveld, L. M. Bruzek, L. Morris, Y. Park, A. A. Adjei, et al. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia Blood, February 15, 2007; 109(4): 1387 - 1394. [Abstract] [Full Text] [PDF]

				Y. Liu, A. Rusinol, M. Sinensky, Y. Wang, and Y. Zou DNA damage responses in progeroid syndromes arise from defective maturation of prelamin A J. Cell Sci., November 15, 2006; 119(22): 4644 - 4649. [Abstract] [Full Text] [PDF]

				V. L.R.M. Verstraeten, J. L.V. Broers, M. A.M. van Steensel, S. Zinn-Justin, F. C.S. Ramaekers, P. M. Steijlen, M. Kamps, H. J.H. Kuijpers, D. Merckx, H. J.M. Smeets, et al. Compound heterozygosity for mutations in LMNA causes a progeria syndrome without prelamin A accumulation Hum. Mol. Genet., August 15, 2006; 15(16): 2509 - 2522. [Abstract] [Full Text] [PDF]

				J. L. V. Broers, F. C. S. Ramaekers, G. Bonne, R. B. Yaou, and C. J. Hutchison Nuclear lamins: laminopathies and their role in premature ageing. Physiol Rev, July 1, 2006; 86(3): 967 - 1008. [Abstract] [Full Text] [PDF]

				A. D. Basso, P. Kirschmeier, and W. R. Bishop Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors J. Lipid Res., January 1, 2006; 47(1): 15 - 31. [Abstract] [Full Text] [PDF]

				L. M. Bruzek, J. N. Poynter, S. H. Kaufmann, and A. A. Adjei Characterization of a Human Carcinoma Cell Line Selected for Resistance to the Farnesyl Transferase Inhibitor 4-(2-(4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide (SCH66336) Mol. Pharmacol., August 1, 2005; 68(2): 477 - 486. [Abstract] [Full Text] [PDF]

				L. G. Fong, J. K. Ng, M. Meta, N. Cote, S. H. Yang, C. L. Stewart, T. Sullivan, A. Burghardt, S. Majumdar, K. Reue, et al. Heterozygosity for Lmna deficiency eliminates the progeria-like phenotypes in Zmpste24-deficient mice PNAS, December 28, 2004; 101(52): 18111 - 18116. [Abstract] [Full Text] [PDF]

				J. E. Karp, J. E. Lancet, S. H. Kaufmann, D. W. End, J. J. Wright, K. Bol, I. Horak, M. L. Tidwell, J. Liesveld, T. J. Kottke, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial Blood, June 1, 2001; 97(11): 3361 - 3369. [Abstract] [Full Text] [PDF]

				A. A. Adjei, J. N. Davis, C. Erlichman, P. A. Svingen, and S. H. Kaufmann Comparison of Potential Markers of Farnesyltransferase Inhibition Clin. Cancer Res., June 1, 2000; 6(6): 2318 - 2325. [Abstract] [Full Text]

				A. A. Adjei, C. Erlichman, J. N. Davis, D. L. Cutler, J. A. Sloan, R. S. Marks, L. J. Hanson, P. A. Svingen, P. Atherton, W. R. Bishop, et al. A Phase I Trial of the Farnesyl Transferase Inhibitor SCH66336: Evidence for Biological and Clinical Activity Cancer Res., April 1, 2000; 60(7): 1871 - 1877. [Abstract] [Full Text]

				J. Broers, B. Machiels, G. van Eys, H. Kuijpers, E. Manders, R van Driel, and F. Ramaekers Dynamics of the nuclear lamina as monitored by GFP-tagged A-type lamins J. Cell Sci., January 10, 1999; 112(20): 3463 - 3475. [Abstract] [PDF]

				F. Kilic, M. B. Dalton, S. K. Burrell, J. P. Mayer, S. D. Patterson, and M. Sinensky In Vitro Assay and Characterization of the Farnesylation-dependent Prelamin A Endoprotease J. Biol. Chem., February 21, 1997; 272(8): 5298 - 5304. [Abstract] [Full Text] [PDF]

				A. Sasseville and Y Raymond Lamin A precursor is localized to intranuclear foci J. Cell Sci., January 1, 1995; 108(1): 273 - 285. [Abstract] [PDF]